nach oben

Acta Diabetologica

Erschienen in:

04.07.2015 | Original Article

Pharmacokinetics of the transdermal delivery of benfotiamine

verfasst von: Zhen Zhu, Gyula Varadi, Stephen G. Carter

Erschienen in: Acta Diabetologica | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Aims

Accumulation of advanced glycation endpoints is a trigger to the development of diabetic peripheral neuropathy, which is a common complication of diabetes. Oral administration of benfotiamine (BFT) has shown some preclinical and clinical promise as a treatment for diabetic peripheral neuropathy. The purpose of this study was to evaluate the method of transdermal delivery of BFT as a possible, viable route of administration for the treatment of diabetic peripheral neuropathy.

Methods

A single application of 10 mg of BFT was given to guinea pigs topically. The levels of thiamine (T), thiamine monophosphate, thiamine diphosphate, S-benzoylthiamine and BFT were measured in the blood, skin and muscle at different time points within 24 h.

Results

At the 24-h time point, following the single BFT dose, the T level was increased 10× in the blood, more than 7× in the skin and almost 4× in the muscle compared to the untreated animals. The total T content (total) was increased 7× in the blood, 17× in the skin and 3× in the muscle compared to the untreated animals.

Conclusions

This strong increase in the tissue levels of T and the associated metabolic derivatives levels found in the blood and local tissues following a single dose indicate that topically applied BFT may be a viable and advantageous delivery method for the treatment of diabetic peripheral neuropathy.

Head KA (2006) Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Altern Med Rev 11(4):294–329PubMed

Tesfaye S, Boulton AJ, Dickenson AH (2013) Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes Care 36(9):2456–2465CrossRefPubMedPubMedCentral

Vincent AM, Calabek B, Roberts L, Feldman EL (2013) Biology of diabetic neuropathy. Handb Clin Neurol 115:591–606CrossRefPubMed

Cameron NE, Gibson TM, Nangle MR, Cotter MA (2005) Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes. Ann N Y Acad Sci 1043:784–792CrossRefPubMed

Duran-Jimenez B, Dobler D, Moffatt S et al (2009) Advanced glycation endproducts in extracellular matrix proteins contribute to the failure of sensory nerve regeneration in diabetes. Diabetes 58:2893–2903CrossRefPubMedPubMedCentral

Stracke H, Hammes HP, Werkmann D et al (2001) Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats. Exp Clin Endocrinol Diabetes 109(6):330–336CrossRefPubMed

Pomero F, Molinar Min A, La Selva M, Allione A, Molinatti GM, Porta M (2001) Benfotiamine is similar to thiamine in correcting endothelial cell defects induced by high glucose. Acta Diabetol 38(3):135–138CrossRefPubMed

Beltramo E, Berrone E, Buttiglieri S, Porta M (2004) Thiamine and benfotiamine prevent increased apoptosis in endothelial cells and pericytes cultured in high glucose. Diabetes Metab Res Rev 20(4):330–336CrossRefPubMed

Gadau S, Emanueli C, Van Linthout S et al (2006) Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/A kt-mediated potentiation of angiogenesis and inhibition of apoptosis. Diabetologia 49(2):405–420CrossRefPubMed

10.

Sánchez-Ramírez GM, Caram-Salas NL, Rocha-González HI et al (2006) Benfotiamine relieves inflammatory and neurophathic pain in rats. Eur J Pharmacol 530(1–2):48–53CrossRefPubMed

11.

Karachalias N, Babaei-Jadidi R, Kupich C, Ahmed N, Thornalley PJ (2005) High-dose thiamine therapy counters dyslipidemia and advanced glycation of plasma protein in streptozotocin-induced diabetic rats. Ann N Y Acad Sci 1043:777–783CrossRefPubMed

12.

Stirban A, Negrean M, Stratmann B et al (2006) Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 29(9):2064–2071CrossRefPubMed

13.

Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG (2008) Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes 116(10):600–605CrossRefPubMed

14.

Haupt E, Ledermann H, Köpcke W (2005) Benfotiamine in the treatment of diabetic polyneuropathy—a three-week randomized, controlled pilot study (BEDIP study). Int J Clin Pharmacol Ther 43(2):71–77CrossRefPubMed

15.

Du X, Edelstein D, Brownlee M (2008) Oral benfotiamine plus alpha-lipoic acid normalises complication-causing pathways in type 1 diabetes. Diabetologia 51(10):1930–1932CrossRefPubMed

16.

Hammes HP, Du X, Edelstein D et al (2003) Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9(3):294–299CrossRefPubMed

17.

Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ (2003) Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 52:2110–2120CrossRefPubMed

18.

Karachalias N, Babaei-Jadidi R, Kupich C, Ahmed N, Thornalley PJ (2005) High dose thiamine therapy counters dyslipidemia and advanced glycation of plasma protein in streptozotocin-induced diabetic rats. Ann N Y Acad Sci 1043:777–783CrossRefPubMed

19.

Booth AA, Khalifah RG, Hudson BG (1996) Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine. BioChem Biophys Res Commun 220:113–119CrossRefPubMed

20.

Wu S, Ren J (2006) Benfotiamine alleviates diabetes-induced cerebral oxidative damage independent of advanced glycation end-product, tissue factor and TNF-Alpha. Neurosci Lett 394(2):158–162CrossRefPubMed

21.

Berg JM, Tymoczko JL, Stryer L (2002) Biochemistry, 5th edn. WH Freeman, New York

22.

Loew D (1996) Pharmacokinetics of thiamine derivatives especially of benfotiamine. Int J Clin Pharmacol Ther 34(2):47–50PubMed

23.

Rabbani N, Shahzad Alam S, Riaz S et al (2009) High dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a pilot randomised, double-blind, placebo-controlled study. Diabetologia 52:208–212CrossRefPubMed

24.

Smithline H, Donnino M, Greenblatt D (2012) Pharmacokinetics of high-dose oral thiamine hydrochloride in healthy subjects. BMC Clin Pharmacol 12:4CrossRefPubMedPubMedCentral

25.

Volvert ML, Seyen S, Piette M et al (2008) Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC Pharmacol 8:10CrossRefPubMedPubMedCentral

26.

Rabbani N, Thornalley PJ (2011) Emerging role of thiamine therapy for prevention and treatment of early-stage diabetic nephropathy. Diabetes Obes Metab 13:577–583CrossRefPubMed

27.

Babaei-Jadidi R, Karachalias N, Kupich C, Ahmed N, Thornalley PJ (2004) High dose thiamine therapy counters dyslipidaemia in streptozotocin-induced diabetic rats. Diabetologia 47:2235–2246CrossRefPubMed

28.

Fraser DA, Diep LM, Hovden IA et al (2012) The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial. Diabetes Care 35(5):1095–1097CrossRefPubMedPubMedCentral

29.

Ziems M, Netzel M, Bitsch I (2000) Biokinetic parameters and metabolism of S-benzoylthiamine-O-monophosphate. BioFactors 11:109–110CrossRefPubMed

30.

Shindo H, Okamoto K, Ji Totsu (1967) Transport of organic compounds through biological membranes. I. Accumulative uptake of S-benzoylthiamine by human erythrocytes. ChemPharmBull 15:295–302

31.

Herve C, Beyne P, Delacoux E (1994) Determination of thiamine and its phosphate esters in human erythrocytes by high-performance liquid chromatography with isocratic elution. J Chromatogr B 653:217–220CrossRef

32.

Lynch PLM, Trimble ER, Young IS (1997) High-performance liquid chromatographic determination of thiamine diphosphate in erythrocytes using internal standard methodology. J Chromatogr B 701:120–123CrossRef

33.

Talwar D, Davidson H, Cooney J, JO’Reilly D (2000) Vitamin B1 status assessed by direct measurement of thiamin pyrophosphate in erythrocytes or whole blood by HPLC: comparison with erythrocyte transketolase activation assay. Clin Chem 46(5):704–710PubMed

34.

Van Landeghem BAJ, Puts J, Claessens HA (2005) The analysis of thiamin and its derivatives in whole blood samples under high pH conditions of the mobile phase. J Chromatogr B 822:316–321CrossRef

35.

Ziems M, Netzel M, Peter S, Bitsch I (1995) Entwicklung einer HPLC-Method zur Bestimmung von Benfotiamin und seinem Metaboliten S-Benzoylthiamin in menschlichem Vollblut. Vitamine und Zusatzstoffe in dr Ernährung von Mensch und Tier, 5. Symposium Jena, pp 320–323

36.

Rogers EF (1972) Modified thiamines. In: Sebrell WH, Harris RS (eds) The vitamins: chemistry, physiology, pathology, methods. Academic Press, New York, pp 130–133

37.

Frank T, Bitsch R, Maiwald J, Stein G (2000) High thiamine diphosphate concentrations in erythrocytes can be achieved in dialysis patients by oral administration of benfotiamine. Eur J Clin Pharmacol 56(3):251–257CrossRefPubMed

38.

Beltramo E, Berrone E, Tarallo S, Porta M (2008) Effects of thiamine and benfotiamine on intracellular glucose metabolism and relevance in the prevention of diabetic complications. Acta Diabetol 45(3):131–141CrossRefPubMed

39.

Jung EH, Takeuchi T, Nishino K, Itokawa Y (1988) Studies on the nature of thiamine pyrophosphate binding and dependency on divalent cations of transketolase from human erythrocytes. Int J Biochemistry 20(11):1255–1259CrossRef

Titel: Pharmacokinetics of the transdermal delivery of benfotiamine
verfasst von: Zhen Zhu
Gyula Varadi
Stephen G. Carter
Publikationsdatum: 04.07.2015
Verlag: Springer Milan
Erschienen in: Acta Diabetologica / Ausgabe 2/2016
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-015-0776-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Aims

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Prevalence of cardiovascular risk factors in youth with type 1 diabetes and elevated body mass index

Aberrant mRNA splicing of paired box 4 (PAX4) IVS7-1G>A mutation causing maturity-onset diabetes of the young, type 9

Relations of vitamin D status, gender and type 2 diabetes in middle-aged Caucasians

Multifactorial intervention in diabetes care using real-time monitoring and tailored feedback in type 2 diabetes

Single patient in GCK-MODY family successfully re-diagnosed into GCK-PNDM through targeted next-generation sequencing technology